Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Top Cited Papers
- 1 April 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (4) , 297-309
- https://doi.org/10.1038/nrc1588
Abstract
The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy. One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-κB (NF-κB), which regulates cell survival. NF-κB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance. What evidence is there that inhibitors of NF-κB might promote apoptosis in cancer cells and can NF-κB inhibitors be used to overcome resistance to chemotherapeutic agents?Keywords
This publication has 118 references indexed in Scilit:
- Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cellsEuropean Journal Of Cancer, 2004
- Intrinsic tumour suppressionNature, 2004
- Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer CellsCancer Research, 2004
- Human breast milk suppresses the transcriptional regulation of IL-1β-induced NF-κB signaling in human intestinal cellsAmerican Journal of Physiology-Cell Physiology, 2004
- HIV-1 Protease Inhibitor, RitonavirCancer Research, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- NF-κB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitorsLeukemia, 2003
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicinOncogene, 2001
- Inhibition of NF-κB Activation by PanepoxydoneBiochemical and Biophysical Research Communications, 1996